AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8185728 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (burst or autodecremental ramp)
Number of subjects: 42
Study 8185728 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing
Number of subjects: 42
Study 8185728 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection algorithms (sudden onset, sustained rate duration, cycle length stability)
Number of subjects: 42
Study 3519005 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.4 microgram/kg)
Number of subjects: 6
Study 3519005 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 6
Study 3519005 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.4 microgram/kg) in subjects with cranial diabetes insipidus
Number of subjects: 6
Study 28952192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber bristles interdental cleaner (RBIC)
Number of subjects: 42
Study 28952192 — intervention group
Group type: COMPARATOR
Intervention: Interdental brush (IDB)
Number of subjects: 42
Study 27102847 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (COC)
Number of subjects: 0
Study 27102847 — intervention group
Group type: COMPARATOR
Intervention: Control bread (CTR)
Number of subjects: 0
Study 27102847 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter (BTR)
Number of subjects: 0
Study 27102847 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapeseed oil (GRP)
Number of subjects: 0
Study 27102847 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (OLV)
Number of subjects: 0
Study 23572444 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-facilitated depression care
Number of subjects: 124
Study 23572444 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 124
Study 22237259 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 242
Study 22237259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 20530648 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapula-oriented exercise group (n = 16)
Number of subjects: 32
Study 20530648 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise group (n = 16)
Number of subjects: 32
Study 18772447 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rt-PA (0.3 mg/kg or 0.45 mg/kg) plus eptifibatide (75 microg/kg bolus followed by 0.75 microg/kg per min infusion for 2 hours)
Number of subjects: 94
Study 18772447 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rt-PA (0.9 mg/kg)
Number of subjects: 94
Study 18772447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment group (low-dose rt-PA plus eptifibatide)
Number of subjects: 94
Study 18772447 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rt-PA group
Number of subjects: 94
Study 18772447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment group
Number of subjects: 94
Study 15889948 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day, N = 370)
Number of subjects: 833
Study 15889948 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (6/25, 6/50, or 12/50 mg/day; N = 86)
Number of subjects: 833
Study 15889948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 377)
Number of subjects: 833
Study 12534412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg b.d. for age 2-3 years; 200 mg b.d. for age 4-11 years; 500 mg b.d. for age > 12 years)
Number of subjects: 100
Study 12534412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12534412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 100
Study 10818026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control policy with a sulphonylurea or insulin
Number of subjects: 3867
Study 10818026 — intervention group
Group type: COMPARATOR
Intervention: Conventional (primarily diet) glucose control policy
Number of subjects: 3867
Study 8679354 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lignocaine-prilocaine) applied for 8 hours after burn injury
Number of subjects: 12
Study 8679354 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment applied to contralateral leg
Number of subjects: 12
Study 8679354 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lignocaine-prilocaine)
Number of subjects: 12
Study 1877711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 60
Study 1877711 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 60
Study 7049583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone 200 mg
Number of subjects: 76
Study 7049583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone 400 mg
Number of subjects: 76
Study 30626406 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Relaxant (MR group)
Number of subjects: 128
Study 30626406 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 128
Study 30445896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir LA 800 mg every 12 weeks after 4 weeks of oral cabotegravir 30 mg
Number of subjects: 115
Study 30445896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) every 12 weeks after 4 weeks of placebo tablets
Number of subjects: 115
Study 27002645 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 0
Study 27002645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24461333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralase 60 kHz laser
Number of subjects: 60
Study 24461333 — intervention group
Group type: COMPARATOR
Intervention: Visumax 500 kHz laser
Number of subjects: 60
Study 22349648 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (4μg/kg)
Number of subjects: 51
Study 22349648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19641353 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus fascial sling procedure incorporated into RRP (group 1)
Number of subjects: 86
Study 19641353 — intervention group
Group type: COMPARATOR
Intervention: Standard RRP without suspension operation (group 2)
Number of subjects: 86
Study 17656420 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D 800 iu plus calcium 1,200 mg
Number of subjects: 205
Study 17656420 — intervention group
Group type: COMPARATOR
Intervention: Daily calcium 1,200 mg (Control)
Number of subjects: 205
Study 17656420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 205
Study 16306204 — intervention group
Group type: EXPERIMENTAL
Intervention: AA1.5 (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 5 h)
Number of subjects: 3
Study 16306204 — intervention group
Group type: EXPERIMENTAL
Intervention: AA3.0 (3.0 g/kg/d for 20 h followed by 1.5 g/kg/d for 5 h)
Number of subjects: 3
Study 16306204 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-Ext (1.5 g/kg/d for 20 h followed by 3.0 g/kg/d for 20 h)
Number of subjects: 3
Study 12421176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 79
Study 12421176 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic colposuspension
Number of subjects: 79
Study 10832809 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg i.v. + 2 microg/kg/min over 24 hours)
Number of subjects: 88
Study 10832809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 9366659 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 80
Study 9366659 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual supportive therapy
Number of subjects: 80
Study 9366659 — intervention group
Group type: COMPARATOR
Intervention: Natural outcome of anorexia nervosa
Number of subjects: 80
Study 1567031 — intervention group
Group type: COMPARATOR
Intervention: Saline (group 0)
Number of subjects: 120
Study 1567031 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 micrograms/kg fentanyl (group 25)
Number of subjects: 120
Study 1567031 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg fentanyl (group 50)
Number of subjects: 120
Study 1567031 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 micrograms/kg fentanyl (group 75)
Number of subjects: 120
Study 1567031 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg and 0.75 micrograms/kg fentanyl
Number of subjects: 120
Study 1567031 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 3901756 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg three times daily
Number of subjects: 10
Study 3901756 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 or 500 mg three times daily
Number of subjects: 10
Study 30504928 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg, iv
Number of subjects: 29
Study 30504928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29246679 — intervention group
Group type: EXPERIMENTAL
Intervention: Finned, cementless central pegged glenoid component (CL component)
Number of subjects: 50
Study 29246679 — intervention group
Group type: COMPARATOR
Intervention: Conventional cemented pegged glenoid component (P component)
Number of subjects: 50
Study 26836763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 3615
Study 26836763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3615
Study 24112594 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum for at least 20 minutes every 2 hours starting at the time of capsule ingestion
Number of subjects: 0
Study 24112594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 0
Study 22144722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal mineral water at 38°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Number of subjects: 63
Study 22144722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal mineral water at 36°C for three weeks, five times a week for 20 minutes a day plus magnetotherapy three times weekly.
Number of subjects: 63
Study 22144722 — intervention group
Group type: COMPARATOR
Intervention: Magnetotherapy only (control group).
Number of subjects: 63
Study 20816153 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular 4.0 Monocryl sutures
Number of subjects: 435
Study 20816153 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel staples
Number of subjects: 435
Study 20816153 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound complication presence
Number of subjects: 435
Study 20816153 — intervention group
Group type: COMPARATOR
Intervention: Comparison of satisfaction between treatment groups
Number of subjects: 435
Study 18446090 — intervention group
Group type: EXPERIMENTAL
Intervention: High daily dose of soy isoflavones (900 mg/day)
Number of subjects: 30
Study 18446090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16181368 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with doxorubicin (20-60 mg) and lipiodol (2-20 mL)
Number of subjects: 89
Study 14600448 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL nonionic contrast material (300 mgI/mL) pushed with 40 mL saline solution
Number of subjects: 78
Study 14600448 — intervention group
Group type: COMPARATOR
Intervention: 120 mL nonionic contrast material (300 mgI/mL) alone
Number of subjects: 78
Study 10386508 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium, 1.25 mg/d
Number of subjects: 677
Study 10386508 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium, 1.25 mg/d plus aspirin, 300 mg/d
Number of subjects: 677
Study 10386508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/d
Number of subjects: 677
Study 10386508 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin therapy aiming at INR of 2.0 to 3.0
Number of subjects: 677
Study 10386508 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 677
Study 10386508 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 677
Study 8698374 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1 g oral azithromycin
Number of subjects: 597
Study 8698374 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline, 100 mg twice daily for seven days
Number of subjects: 597
Study 1898642 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-beat analysis method for estimating Ees
Number of subjects: 29
Study 1898642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (5 micrograms/kg/min i.v.)
Number of subjects: 29
Study 1898642 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ees
Number of subjects: 29
Study 29282203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral/nutritional modification program to decrease fat and increase vegetable, fruit, and grain intake for an average of 8.1 years
Number of subjects: 48835
Study 29282203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral/nutritional modification program
Number of subjects: 48835
Study 26965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting ACS guidelines for smoking and body weight/physical activity/dietary/alcohol
Number of subjects: 61098
Study 26965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting 1 guideline
Number of subjects: 61098
Study 26965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting 2 guidelines
Number of subjects: 61098
Study 26965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting 3 guidelines
Number of subjects: 61098
Study 26965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting 4 guidelines
Number of subjects: 61098
Study 26965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers and non/moderate alcohol drinkers
Number of subjects: 61098
Study 26965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants without baseline chronic disease
Number of subjects: 61098
Study 25335326 — intervention group
Group type: EXPERIMENTAL
Intervention: Qizhi Jiangtang Capsule (QJC), 5 pills per time, 3 times a day
Number of subjects: 168
Study 25335326 — intervention group
Group type: COMPARATOR
Intervention: Valsartan Capsule 160 mg, once daily
Number of subjects: 168
Study 25335326 — intervention group
Group type: EXPERIMENTAL
Intervention: Qizhi Jiangtang Capsule (QJC)
Number of subjects: 168
Study 22088966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (five or more portions of FV per day)
Number of subjects: 81
Study 22088966 — intervention group
Group type: COMPARATOR
Intervention: Control group (two or fewer portions of FV per day)
Number of subjects: 81
Study 22088966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 81
Study 22088966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 20187965 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and lifestyle intervention
Number of subjects: 800
Study 20187965 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study 18596517 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade fenestration tubes
Number of subjects: 25
Study 18596517 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde fenestration tubes
Number of subjects: 25
Study 18596517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dome fenestration tubes
Number of subjects: 25
Study 18596517 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with fenestration tubes
Number of subjects: 25
Study 15752839 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521)/AIDSVAX B/E gp120 prime-boost vaccine
Number of subjects: 123
Study 15752839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 12052587 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial coagulation
Number of subjects: 120
Study 12052587 — intervention group
Group type: COMPARATOR
Intervention: Endometrial resection
Number of subjects: 120
Study 10587596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing sealant applied to 112 teeth after bracket placement.
Number of subjects: 20
Study 10587596 — intervention group
Group type: COMPARATOR
Intervention: Control group with 113 teeth that did not receive the fluoride-releasing sealant.
Number of subjects: 20
Study 8556996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg kg‐1 rocuronium in obese patients
Number of subjects: 48
Study 8556996 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg kg‐1 rocuronium in all groups
Number of subjects: 48
Study 1991925 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam treatment
Number of subjects: 21
Study 1991925 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests (STs) with aztreonam reagents
Number of subjects: 21
Study 1991925 — intervention group
Group type: COMPARATOR
Intervention: Skin tests (STs) with penicilloyl-polylysine (PPL) and penicillin minor determinant mixture
Number of subjects: 21
Study 1991925 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PPL-specific IgE antibodies
Number of subjects: 21
Study 1991925 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PPL-specific IgG antibodies
Number of subjects: 21
Study 1991925 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerance of aztreonam
Number of subjects: 21
Study 1991925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caution with aztreonam
Number of subjects: 21
Study 6173900 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous leukocyte interferon therapy as adjuvant treatment
Number of subjects: 0
Study 6173900 — intervention group
Group type: COMPARATOR
Intervention: Concurrent control group
Number of subjects: 0
Study 31836017 — intervention group
Group type: EXPERIMENTAL
Intervention: iHIVARNA-01
Number of subjects: 0
Study 31836017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30203668 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Model
Number of subjects: 202
Study 30203668 — intervention group
Group type: COMPARATOR
Intervention: Augmented Standard Care
Number of subjects: 202
Study 30203668 — intervention group
Group type: COMPARATOR
Intervention: Resource Nurse Care
Number of subjects: 202
Study 26977626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (1000 mg/day for 14-15 days)
Number of subjects: 109
Study 26977626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mexidol)
Number of subjects: 109
Study 26977626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 109
Study 26977626 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study 24813928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations evaluated on the third day by an infectious disease specialist.
Number of subjects: 3192
Study 24813928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations with dose adjustment or change of route.
Number of subjects: 3192
Study 24813928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations that were personally commented on.
Number of subjects: 3192
Study 24813928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention of antibiotic prescription recommendations overall.
Number of subjects: 3192
Study 21988468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime continuous infusion (4g after 2g loading dose for MDRD 10-30 ml/min, 6g for MDRD 40-80 ml/min, 8g for MDRD 90-110 ml/min, 10g for MDRD 120-190 ml/min, 12g/day for MDRD >200 ml/min)
Number of subjects: 0
Study 21988468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime continuous infusion
Number of subjects: 0
Study 19106729 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet portal-based coaching intervention
Number of subjects: 241
Study 19106729 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 241
Study 19106729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 241
Study 16236557 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group in two-armed trials
Number of subjects: 65
Study 16236557 — intervention group
Group type: EXPERIMENTAL
Intervention: Various reasons for using unequal randomisation
Number of subjects: 65
Study 16236557 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 65
Study 14558210 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening
Number of subjects: 1173
Study 10782805 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5, 10, or 20 mg/kg)
Number of subjects: 28
Study 10782805 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg)
Number of subjects: 28
Study 10782805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8988539 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐A, ‐B, ‐C, ‐DR and ‐DQ phenotypes analysis
Number of subjects: 22854
Study 8988539 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA haplotype frequencies analysis
Number of subjects: 22854
Study 8988539 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic tree analysis based on HLA gene frequencies
Number of subjects: 22854
Study 8988539 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise test for Hardy‐Weinberg equilibrium
Number of subjects: 22854
Study 1457267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg as capsules) and soluble paracetamol (1 g)
Number of subjects: 8
Study 1457267 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg as capsules)
Number of subjects: 8
Study 6379120 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (F DAT)
Number of subjects: 40
Study 6379120 — intervention group
Group type: COMPARATOR
Intervention: Attenuated dosage daunorubicin, cytosine arabinoside, and 6-thioguanine (At DAT)
Number of subjects: 40
Study 31195056 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tSMS
Number of subjects: 23
Study 31195056 — intervention group
Group type: EXPERIMENTAL
Intervention: MonoAP TMS
Number of subjects: 23